Therapeutic Potential of Targeted Mucosal Heme Oxygenase-1 in Colitis
靶向粘膜血红素加氧酶 1 在结肠炎中的治疗潜力
基本信息
- 批准号:10552610
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-01-01 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptive TransferAgeAnimal ModelAnti-Inflammatory AgentsAwardBiliverdineBiochemicalBiologicalBiologyBone MarrowCarbon MonoxideCellsChronicClinicalColitisComplexCytoprotectionDataDevelopmentDiseaseDrug CombinationsEnteralEnzymesEpithelial CellsEpitheliumEquilibriumFundingGastroenterologistHemeHomeostasisHospitalizationHumanHypoxiaHypoxia Inducible FactorImmunosuppressionInflammationInflammatoryInflammatory Bowel DiseasesInstitutionInterleukin-10Intestinal MucosaIronKnock-outLinkMacrophageMalignant NeoplasmsMeasuresMentorsMetabolicModelingMucosal Immune SystemMucositisMucous MembraneMusMyelogenousOxidative StressOxygenPathway interactionsPatientsPharmaceutical PreparationsPhysiciansPredispositionProcollagen-Proline DioxygenaseProtein IsoformsRegulationResearchRiskRoleScientistSignal TransductionStimulusStressStructureTestingTherapeuticTimeTissuesTrainingTranscription CoactivatorTranslatingTranslationsVeteransbHLH-PAS factor HLFcareer developmentchemokinecostcytokinedefined contributiondesigndimerdisorder controlefficacy testingexperiencegene repressiongut inflammationheme oxygenase-1hospitalization rateshypoxia inducible factor 1improvedinfection riskinterestintestinal epitheliummilitary veteranmouse modelmurine colitisnovelnovel strategiesolder patientresponsetherapeutic targettranscription factor
项目摘要
Disruptions in the complex balance between inflammatory and homeostatic signaling in the intestinal mucosa
can result in diseases such as inflammatory bowel disease (IBD). From this perspective, there is significant
interest in identifying endogenous homeostatic pathways in the intestinal mucosa. Targeted activation of these
mucosal pathways may restore homeostasis and at the same time avoid the risks of systemic
immunosuppression which is frequently utilized for control of IBD. Heme oxygenase-1 (HO-1) and its metabolic
by-product carbon monoxide are activated in the setting of oxidative stress. Stimulation of this pathway has
been demonstrated to be protective in several murine models of IBD. Activation of the HO-1 pathway in
macrophages has been shown to augment bacterial killing and negatively regulate proinflammatory cytokine
expression in the intestinal mucosa. We have also identified an anti-inflammatory role for intestinal epithelial
HO-1. Hypoxia inducible factor (HIF) is a transcription factor that is activated in the setting of hypoxic stress.
Stabilization of epithelial HIF is protective against intestinal inflammation. It is a transcriptional activator of HO-
1 but a relationship between the protective impact of HIF and HO-1 in chronic intestinal inflammation has not
previously been established, nor has the regulatory relationship between the two been examined in intestinal
epithelial cells or macrophages. The proposed project will test the hypothesis that stabilization of HIF in
intestinal epithelial cells and MΦ is protective against intestinal inflammation through induction of HO-1. Based
on our preliminary data, this is pursued with the following objectives: 1. Define the contribution of HO-1 to the
protective impact of epithelial HIF in mucosal inflammation. 2. Determine if myeloid HIF is protective against
intestinal inflammation through HO-1. 3. Test the efficacy of selective induction of HIF/HO-1 for amelioration of
chronic intestinal inflammation. This proposed project is part of a plan to support the Candidate's career
development into an independently funded, VA-based, physician-scientist through an appropriately structured
combination of research, training and mentoring activities. The Candidate is a gastroenterologist with a focus
on IBD and homeostatic pathways of the mucosal immune system. With the support of this award, a nationally
recognized research institution, and experienced mentors, this project will advance expertise in integrated
mucosal biology and proficiency in therapeutic modulation of mucosal anti-inflammatory pathways for
treatment of IBD.
肠粘膜炎症和稳态信号之间复杂平衡的破坏
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joseph Onyiah其他文献
Joseph Onyiah的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joseph Onyiah', 18)}}的其他基金
Therapeutic Potential of Targeted Mucosal Heme Oxygenase-1 in Colitis
靶向粘膜血红素加氧酶 1 在结肠炎中的治疗潜力
- 批准号:
9906044 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Therapeutic Potential of Targeted Mucosal Heme Oxygenase-1 in Colitis
靶向粘膜血红素加氧酶 1 在结肠炎中的治疗潜力
- 批准号:
10265391 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Therapeutic Potential of Targeted Mucosal Heme Oxygenase-1 in Colitis
靶向粘膜血红素加氧酶 1 在结肠炎中的治疗潜力
- 批准号:
10438663 - 财政年份:2019
- 资助金额:
-- - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
-- - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
-- - 项目类别:














{{item.name}}会员




